Skip to main content

Month: February 2023

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90) Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial responses Manageable overall safety profile observed across multiple expansion cohorts Company plans to initiate Phase 2 study in mCRPC in 2023ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) —   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from the dose expansion phase of the Company’s ongoing Phase 1 clinical trial of lorigerlimab, a...

Continue reading

TaskUs Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

NEW BRAUNFELS, Tx., Feb. 13, 2023 (GLOBE NEWSWIRE) — TaskUs, Inc (Nasdaq: TASK), a provider of outsourced digital services and next-generation customer experience to fast-growing technology companies, will report its fourth quarter and full year 2022 financial results after the market close on February 27, 2023. On that day management will host a conference call and webcast at 5:00 p.m. ET to discuss the company’s business and financial results. Investors and other interested parties can access the call and webcast in the following ways: What: TaskUs Fourth Quarter and Full Year 2022 Conference Call and webcast When: Monday, February 27, 2023 Time: 5:00 p.m. ET Toll-Free and Toll Dial-In Numbers: 877-407-2988 / +1 201-389-0923 Live Webcast: https://ir.taskus.com/ Replay: An archived webcast of the conference call will be accessible...

Continue reading

United Community Banks, Inc. and First Miami Bancorp, Inc. Announce Merger Agreement

Strengthening Position in Vibrant Miami Market GREENVILLE, S.C. and SOUTH MIAMI, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NASDAQ: UCBI) (“United”) and First Miami Bancorp, Inc. (OTC: FMIA) (“First Miami”) announced today the execution of a definitive merger agreement pursuant to which United will acquire First Miami, and its wholly-owned subsidiary, First National Bank of South Miami (“FNBSM”) (the “Merger”), in an all-stock transaction with an aggregate value of approximately $115.9 million, or $1,330 per share of First Miami common stock, based on United’s 10-day average closing stock price of $33.02 as of February 10, 2023. Additionally, First Miami shareholders will receive a special cash dividend at closing from net proceeds of the sale of certain investment securities held by First Miami. FNBSM...

Continue reading

Datasea Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Business Updates

BEIJING, Feb. 13, 2023 (GLOBE NEWSWIRE) — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), incorporated in Nevada in September 2014, is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city in China, today announced financial results for the quarter ended December 31, 2022, and provided an update on its key strategic and operational initiatives. “As we progressed through the second quarter, it became evident that the evolving Covid-19 pandemic and the changing prevention and control mechanisms would significantly impact our quarterly earnings and ability to fulfill customer orders, we also adjust our internal policy on 5G SMS business. Therefore, our second quarter revenue was not in-line with our expectations,” said Zhixin Liu,...

Continue reading

Great Elm Group Reports Fiscal 2023 Second Quarter Financial Results

Company to Host Conference Call at 9:00 a.m., ET, on February 14, 2023 WALTHAM, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Great Elm Group, Inc. (“we,” “our,” “GEG,” or “Great Elm”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal second quarter ended December 31, 2022. Transformational TransactionsOn January 3, 2023, GEG sold its Durable Medical Equipment (“DME”) business for $80 million. After settling all obligations, the transaction resulted in approximately $26 million in net cash proceeds and 346,028 shares of Quipt common stock. On December 30, 2022, GEG entered into an agreement to sell 61% of the equity interests in Forest Investments, Inc. (“Forest”) and on January 17, 2023 it exercised a put right for the remaining 19% of the equity interests in Forest for aggregate cash...

Continue reading

Vornado Announces Fourth Quarter 2022 Financial Results

NEW YORK, Feb. 13, 2023 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE: VNO) reported today: Quarter Ended December 31, 2022 Financial Results NET LOSS attributable to common shareholders for the quarter ended December 31, 2022 was $493,280,000, or $2.57 per diluted share, compared to net income attributable to common shareholders of $11,269,000, or $0.06 per diluted share, for the prior year’s quarter. Adjusting for the items that impact period-to-period comparability listed in the table on the following page, net income attributable to common shareholders, as adjusted (non-GAAP) for the quarter ended December 31, 2022 was $19,954,000, or $0.10 per diluted share, and $22,977,000, or $0.12 per diluted share for the quarter ended December 31, 2021. FUNDS FROM OPERATIONS (“FFO”) attributable to common shareholders...

Continue reading

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers Transaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisition Employees associated with commercial, operations, R&D and supporting functions expected to join CytekSALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale...

Continue reading

MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test

NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that UnitedHealthcare will cover the mdxhealth Genomic Prostate Score (GPS) test (formerly Oncotype DX GPS) under UnitedHealthcare’s commercial policies to assist with treatment decisions for individuals newly diagnosed with localized prostate cancer and meeting coverage criteria. Michael K. McGarrity, CEO of mdxhealth, commented: “We are very pleased to announce that UnitedHealthcare, the largest private health insurer in the United States, will provide coverage for our Genomic...

Continue reading

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements: Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: “Today, Sorrento Therapeutics, Inc. and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (“Scintilla”), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).  While Scilex is...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.